CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: A dose-escalation and dose-expansion phase 1 study

The Lancet Oncology

Volumn 16, Issue 8, 2015, Pages 949-956

  Cassier, Philippe A ^a   Italiano, Antoine ^b   Gomez Roca, Carlos A ^c   Le Tourneau, Christophe ^d   Toulmonde, Maud ^b   Cannarile, Michael A ^e   Ries, Carola ^e   Brillouet, Anne ^f   Müller, Claudia ^e   Jegg, Anna Maria ^e   Bröske, Ann Marie ^e   Dembowski, Markus ^f   Bray French, Katharine ^f   Freilinger, Christine ^f   Meneses Lorente, Georgina ^g   Baehner, Monika ^e   Harding, Ross ^g   Ratnayake, Jayantha ^g   Abiraj, Keelara ^f   Gass, Nathalie ^f   Noh, Karen ^h   Christen, Randolph D ^f   Ukarma, Lidia ^f   Bompas, Emmanuelle ⁱ   Delord, Jean Pierre ^c,d   Blay, Jean Yves ^a   Rüttinger, Dominik ^e   more..

^a CENTRE LÉON BÉRARD   (France)

^b INSTITUT BERGONIÉ   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d INSTITUT CURIE   (France)

^e ROCHE INNOVATION CENTER MUNICH   (Germany)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g ROCHE PRODUCTS LTD   (United Kingdom)

^h Roche Pharmaceutical Research and Early Development   (United States)

ⁱ NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EMACTUZUMAB; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL ARTICLE; DERMATITIS; DERMOHYPODERMITIS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; EYELID EDEMA; FACE EDEMA; FATIGUE; FEMALE; GIANT CELL TUMOR; HUMAN; HUMAN TISSUE; LACRIMATION DISORDER; LUPUS ERYTHEMATOSUS; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SKIN LUPUS ERYTHEMATOSUS; SOFT TISSUE TUMOR; TREATMENT OUTCOME; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; GIANT CELL TUMORS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; SOFT TISSUE NEOPLASMS; SYNOVITIS, PIGMENTED VILLONODULAR; TIME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GIANT CELL TUMORS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; SOFT TISSUE NEOPLASMS; SYNOVITIS, PIGMENTED VILLONODULAR; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938090300     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00132-1     Document Type: Article

References (32)

1. Wardelmann E, Schildhaus HU, Merkelbach-Bruse S, et al. Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies. Ann Oncol 2010, 21:265-269.
2. Tenosynovial giant cell tumour, localized type and diffuse type. WHO classification of tumours of soft tissue and bone 2013, International Agency for Research on Cancer, IARC, Lyon. C.D. Fletcher, J.A. Bridge, P.C.M. Hogendoorn, F. Mertens (Eds.).
3. Sirlyn Q Pigmented villonodular synovitis. Sonography 2014, 1:19-24.
4. Murphey MD, Rhee JH, Lewis RB, Fanburg-Smith JC, Flemming DJ, Walker EA Pigmented villonodular synovitis: radiologic-pathologic correlation. Radiographics 2008, 28:1493-1518.
5. Verspoor F, van der Geest I, Vegt E, Veth R, van der Graaf WT, Schreuder B Pigmented villonodular synovitis: current concepts about diagnosis and management. Future Oncol 2013, 9:1515-1531.
6. Ohjimi Y, Iwasaki H, Ishiguro M, et al. Short arm of chromosome 1 aberration recurrently found in pigmented villonodular synovitis. Cancer Genet Cytogenet 1996, 90:80-85.
7. Mertens F, Orndal C, Mandahl N, et al. Chromosome aberrations in tenosynovial giant cell tumors and nontumorous synovial tissue. Genes Chromosomes Cancer 1993, 6:212-217.
8. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 2006, 103:690-695.
9. Blay JY, El Sayadi H, Thiesse P, Garret J, Ray-Coquard I Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 2008, 19:821-822.
10. Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 2012, 118:1649-1655.
11. Gelderblom H, Pérol D, Chevreau C, et al. An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment. Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 10516.
12. Stacchiotti S, Crippa F, Messina A, et al. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. Clin Sarcoma Res 2013, 3:8.
13. Ries CH, Cannarile MA, Hoves S, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014, 25:846-859.
14. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35:1773-1782.
15. Common Terminology Criteria for Adverse Events (CTCAE), version 4.03 National Cancer Institute, (accessed Dec 22, 2014). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf.
16. Deininger M, Buchdunger E, Druker BJ The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653.
17. Taylor JR, Brownlow N, Domin J, Dibb NJ FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene 2006, 25:147-151.
18. Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005, 105:3127-3132.
19. Cheng H, Clarkson PW, Gao D, Pacheco M, Wang Y, Nielsen TO Therapeutic antibodies targeting CSF1 impede macrophage recruitment in a xenograft model of tenosynovial giant cell tumor. Sarcoma 2010, 2010:174528.
20. Tap W, Anthony S, Chmielowski B, et al. A pilot study of PLX3397, a selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor, in pigmented villonodular synovitis (PVNS). Proc Am Soc Clin Oncol 2014, 32(suppl). abstr 10503.
21. Guilhot F Indications for imatinib mesylate therapy and clinical management. Oncologist 2004, 9:271-281.
22. McClelland CM, Harocopos GJ, Custer PL Periorbital edema secondary to imatinib mesylate. Clin Ophthalmol 2010, 4:427-431.
23. Larson JS, Bergstrom LK, Cameron JD, Erickson LA, Grimm TE Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia. Arch Ophthalmol 2007, 125:985-986.
24. Esmaeli B, Prieto VG, Butler CE, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 2002, 95:881-887.
25. Hume DA Macrophages as APC and the dendritic cell myth. J Immunol 2008, 181:5829-5835.
26. Radi ZA, Koza-Taylor PH, Bell RR, et al. Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury. Am J Pathol 2011, 179:240-247.
27. Hambleton J, Zhou L, Rogers S, et al. A phase 1 study of FPA008, an anti-colony stimulating factor 1 receptor (anti-CSF1R) antibody in healthy volunteers and subjects with rheumatoid arthritis (RA): preliminary results. Arthritis Rheumatol 2014, 66:S657.
28. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988, 15:1833-1840.
29. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med 2002, 347:472-480.
30. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010, 28:1772-1779.
31. Italiano A, Delcambre C, Hostein I, et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol 2010, 21:1135-1137.
32. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. New Engl J Med 2010, 363:1727-1733.